Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

XG 102

Known as: XG-102, XG102 peptide 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

D-JNKI-1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Postoperative Ocular Inflammation: A Single Subconjunctival Injection of XG-102 Compared to Dexamethasone Drops in a Randomized Trial.
PURPOSE To evaluate the efficacy and safety of XG-102 (brimapitide) compared to dexamethasone eye drops in the treatment of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study.
Abstract Purpose: We aimed to investigate the safety, tolerability, and systemic diffusion of a single escalating dose of XG-102… Expand
2015
2015
Subconjunctival injection of XG-102, a c-Jun N-terminal kinase inhibitor peptide, in the treatment of endotoxin-induced uveitis in rats.
PURPOSE XG-102, a TAT-coupled dextrogyre peptide inhibiting the c-Jun N-terminal kinase, was shown efficient in the treatment of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study.
PURPOSE We aimed to investigate the safety, tolerability, and systemic diffusion of a single escalating dose of XG-102 (a 31-D… Expand
  • table 1
  • table 2
  • figure 2
2014
2014
XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study
The aim of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of the JNK inhibitor XG‐102 in a… Expand
2012
2012
The JNK Inhibitor XG-102 Protects against TNBS-Induced Colitis
The c-Jun N-terminal kinase (JNK)-inhibiting peptide D-JNKI-1, syn. XG-102 was tested for its therapeutic potential in acute… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 7
2010
2010
The c‐Jun N‐terminal kinase (JNK) inhibitor XG‐102 enhances the neuroprotection of hyperbaric oxygen after cerebral ischaemia in adult rats
J‐R. Liu, Y. Zhao, A. Patzer, N. Staak, R. Boehm, G. Deuschl, J. Culman, C. Bonny, T. Herdegen and C. Eschenfelder (2010… Expand
2010
2010
A peptide inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced uveitis.
PURPOSE To evaluate the effect of XG-102 (formerly D-JNKI1), a TAT-coupled dextrogyre peptide that selectively inhibits the c-Jun… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
c-Jun N-Terminal Kinase Pathway Inhibition in Intracerebral Hemorrhage
Background: Inhibition of the c-Jun N-terminal kinase (JNK) pathway by the TAT-coupled peptide XG-102 (formerly D- JNKI1) induces… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
The JNK Inhibitor XG-102 Protects from Ischemic Damage with Delayed Intravenous Administration Also in the Presence of Recombinant Tissue Plasminogen Activator
Background: XG-102 (formerly D-JNKI1), a TAT-coupled dextrogyre peptide which selectively inhibits the c-Jun N-terminal kinase… Expand
  • table 1
  • figure 1
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE